Adamed Discovery was opened in Kajetany – a modern research center that can accelerate the development of Polish drugs for cancer,dementia and other diseases.

Adamed Pharma has launched a new Adamed Discovery Research and Development Center in Kajetany near Warsaw,focusing on the development of original therapies in the areas of oncology,neuropsychiatry and mRNA vaccines. This is an investment worth PLN 90 million and one of the most modern facilities of this type in Central Europe,equipped with laboratories that use artificial intelligence and automation tools. The goal is clear – a Polish medicine for previously incurable diseases.

A new era of Polish research

The Adamed Discovery Center has over 3.5 thousand square meters,most of which is occupied by laboratories and research spaces. A team of about 40 scientists – chemists and biotechnologists – is already working on five research programs,including new oncology molecules. As emphasized by Małgorzata Adamkiewicz,MD,PhD,Chairwoman of the Supervisory Board of Adamed Pharma: “Poland has the potential and talents to create its own,original medicine. We are determined to do it.”

Equipping the center with advanced AI-based platforms allows scientists to integrate conceptual work,hypothesis testing,preclinical development and laboratory testing under one roof. “We have equipped them with platforms based on automation and artificial intelligence,which allows us to combine hypothesis testing,molecular identification,laboratory work and preclinical development under one roof. This speeds up the entire research process and increases its efficiency,” explains Dr. Nicolas Beuzen,Director of Innovative Medicines Development and Strategic Partnerships at Adamed Discovery.

A response to the challenges of modern medicine

One of the company’s key motivations is the fight against cancer and neurodegenerative diseases. – “Today,one of the most important challenges is the fight against cancer. In Poland,this disease claims 100,000 lives a year,and over a million Poles live with cancer. According to the OECD,the incidence will grow even faster than in other EU countries,” emphasized Dr. Adamkiewicz during the opening. Adamed has already allocated PLN 450 million for oncology projects and plans further investments in therapies for patients with cancer and dementia,which is increasing rapidly with the aging of society.

The group uses its experience to – as Adamkiewicz says – “respond to the challenges of modern medicine from the very beginning of the company’s existence.” She recalled that Adamed started developing its own products in the 1980s,when there was a lack of modern therapies. Currently,the company’s portfolio includes nearly 900 products available on six continents.

Groundbreaking research programs and collaborations

Adamed Discovery is currently conducting five projects,and one of the key ones,ONCO51 – an oncology drug candidate – is already in an advanced phase of clinical trials.

“The ONCO51 program,which went from the initial concept to the first administration of the drug to patients,shows that we can turn bold scientific ideas into therapies that reach the clinic,” concludes Dr. Beuzen.

The company focuses on cooperation with the scientific community and universities in Poland,and multidisciplinary research teams combine specialists from business and science. – “For over 20 years,we have been building a bridge between the worlds of science and business. We focus on multidisciplinary teams and connect experts in many fields so that scientists and entrepreneurs understand each other better. In this way,research projects are created that have a real chance of leading to the development of new,original medicines,” emphasizes Dr. Bartłomiej Żerek,director of the innovation department at Adamed Discovery.

Contribution to the Polish economy and science

Since the beginning of its operations,Adamed has been investing intensively in research – the company has already spent PLN 2.4 billion on R&D,including PLN 600 million on the development of new drugs. The value of the center in Kajetany alone is almost PLN 90 million.

Michał Jaros,Deputy Minister of Development and Technology,who was present at the opening,commented on the new investment: “In times of global challenges,such projects strengthen the country’s resilience and create the advantage we need most today. Congratulations to the entire Adamed team. This is what a modern,ambitious Poland looks like!”

Adamed Discovery emphasizes its role as a pioneer – the company was the first in Poland to start large-scale research on original drugs. The integration of the research community,business and international partners puts Adamed in line with the largest players in global pharmacy. The company’s products are available in nearly 60 countries,and the company is already protected by 256 patents.

Future potential

The Adamed Discovery team of scientists is convinced that Poland – with appropriate support – is ready to create an innovative medicine tailored to global markets. Dr. Adamkiewicz points to the positive example of the Danish Ozempic as an inspiration and development potential for the domestic biotech industry: “The example of Denmark,where Ozempic has become a driving force of economic growth,shows the power of an innovative drug.”

The company emphasizes that the strategy of investing in Polish research and new technologies is no longer just a vision,but a real business plan. The combination of science,financing and the courage to take risks has made Poland a significant player on the map of pharmaceutical innovation,and the new Adamed Discovery center is a symbol of this change.